Aktis Oncology Starts Second Phase 1b Trial for AKY-2519 in Lung and Other Solid Tumors
AKTS sits 31% above its 52-week low of $14.72.
Summary
Aktis Oncology has initiated the Phase 1b BActinium-2 trial of AKY-2519, its B7-H3 targeting miniprotein radioconjugate, in patients with NSCLC and other B7-H3 expressing solid tumors. This is the second Phase 1b trial for the asset, following the BActinium-1 trial in mCRPC that began in May 2026. The trial will explore three dose levels with the ability to expand enrollment at selected doses. The company cites first-in-human imaging and dosimetry data from ASCO 2026 showing robust tumor uptake and retention with limited normal tissue exposure, supporting a potentially wide therapeutic window. This broadens the clinical development of AKY-2519 into a large patient population and adds a second active Phase 1b program alongside the ongoing NECTINIUM-2 trial for AKY-1189. Preliminary data from BActinium-1 is expected in 2027, and from NECTINIUM-2 in Q1 2027.
At the time of this announcement, AKTS was trading at $19.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.72 to $34.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.